Home > Oncology > ESMO 2022 > Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab

Presented By
Dr John Haanen, Netherlands Cancer Institute, the Netherlands
Conference
ESMO 2022
Trial
Phase 3
Second-line treatment with tumour-infiltrating lymphocytes (TIL) improves progression-free survival (PFS) compared with ipilimumab in patients with advanced, non-resectable stage III–IV melanoma, results from an investigator-driven randomised phase 3 trial show. Although immune checkpoint inhibitors and targeted therapies have profoundly improved outcome of patients with (advanced) melanoma, approximately 50% of patients still die from their disease within 5 years following diagnosis of stage IV disease [1]. Thus, there is a great unmet need for novel treatment options in this patient population. Adoptive cell therapy with TIL is a (elaborative and time-consuming) treatment modality with promising response rates of 36–70% in heavily pre-treated patients with advanced melanoma, observed in multiple phase 1/2 trials [2,3]. Dr John Haanen (Netherlands Cancer Institute, the Netherlands) and colleagues performed the first investigator-driven, open-label, rando...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on